CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) [Yahoo! Finance]
CSL LTD SP/ADR (CSLLY)
NASDAQ:AMEX Investor Relations:
csl.com/investors
Company Research
Source: human
Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There were no major safety or tolerability concerns with CSL112. "We look forward to sharing our scientific learnings regarding cholesterol efflux and recurrent cardiovascular events," said C. Michael Gibson , M.S., M.D., Baim Institute for Clinical Research, Harvard Medical School . "We will continue to analyze the findings and share the full results in the coming months." Further analysis of AEGIS-II is ongoing and primary results will be presented at the American College of Cardiology Scientific Sessions, held April 6, 2024 , and published in a peer-reviewed journal. "Substantial work rema
Show less
Read more
Impact Snapshot
Event Time:
CSLLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSLLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSLLY alerts
High impacting CSL LTD SP/ADR news events
Weekly update
A roundup of the hottest topics
CSLLY
News
- Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons [Yahoo! Finance]Yahoo! Finance
- Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three SeasonsPR Newswire
- Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens [Yahoo! Finance]Yahoo! Finance
- Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia TeensGlobeNewswire
- Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL" [Yahoo! Finance]Yahoo! Finance